Credit Suisse AG lifted its position in Becton Dickinson and Co (NYSE:BDX) by 6.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,139 shares of the medical instruments supplier’s stock after acquiring an additional 28,234 shares during the period. Credit Suisse AG’s holdings in Becton Dickinson and were worth $121,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Acropolis Investment Management LLC purchased a new stake in Becton Dickinson and in the third quarter valued at $101,000. Truvestments Capital LLC purchased a new stake in Becton Dickinson and in the third quarter valued at $105,000. Almanack Investment Partners LLC. purchased a new stake in Becton Dickinson and in the second quarter valued at $105,000. Bartlett & Co. LLC boosted its holdings in Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares during the last quarter. Finally, Bridgeworth LLC purchased a new stake in Becton Dickinson and in the second quarter valued at $131,000. 86.25% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Charles R. Bodner sold 2,080 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the transaction, the senior vice president now owns 4,497 shares in the company, valued at approximately $1,105,497.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,243 shares of the company’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $243.86, for a total transaction of $1,278,557.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 75,908 shares of company stock valued at $18,085,616. Insiders own 1.00% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the firm earned $2.40 EPS. The company’s revenue for the quarter was up 39.0% on a year-over-year basis. On average, sell-side analysts expect that Becton Dickinson and Co will post 12.1 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Monday, December 10th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Friday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio is 27.25%.
Several equities research analysts have commented on BDX shares. KeyCorp reaffirmed a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Citigroup lowered their price target on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Barclays assumed coverage on shares of Becton Dickinson and in a research note on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Morgan Stanley increased their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $253.79.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Story: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.